In the present study we determined the long-term effects of persistent, local insulin-like growth factor I (IGF-I) expression on cardiac function in the SIS2 transgenic mouse. Cardiac mass/ tibial length was increased in SIS2 mice by 10 wk of age; this cardiac hypertrophy became more pronounced later in life. Peak aortic outflow velocity, a correlate of cardiac output, was increased at 10 wk in SIS2 mice but was decreased at 52 wk. 72 wk SIS2 mouse hearts exhibited wide variability in the extent of cardiac hypertrophy and enlargement of individual cardiac myofibers. Sirius red staining revealed increased fibrosis in 72 wk SIS2 hearts. Persistent local IGF-I expression is sufficient to initially induce an analog of physiological cardiac hypertrophy in which peak aortic outflow velocity is increased relative to controls in the absence of any observed detrimental histological changes. However, this hypertrophy progresses to a pathological condition characterized by decreased systolic performance and increased fibrosis. Our results confirm the shortterm systolic performance benefit of increased IGF-I, but our demonstration that IGF-I ultimately diminishes systolic performance raises doubt about the therapeutic value of chronic IGF-I administration. Considering these findings, limiting temporal exposure to IGF-I seems the most likely means of delivering IGF-I's potential benefits while avoiding its deleterious side effects.-Delaughter, M. C., Taffet, G. E., Fiorotto, M. L., Entman, M. L., Schwartz, R. J. Local insulin-like growth factor I expression induces physiologic, then pathologic, cardiac hypertrophy in transgenic mice. FASEB J. 13, 1923-1929 (1999) 
myocardial infarction. Mild or short-term overload induces physiological hypertrophy, in which the heart enlarges until it establishes a new operational plateau. Severe and/or persistent overload leads to pathological hypertrophy, characterized by myofiber disorganization, increased fibrosis and decreased cardiac output despite greater cardiac mass.
Insulin-like growth factor I (IGF-I) is a 70 amino acid peptide hormone produced primarily by the liver in adults in response to growth hormone (GH) secretion by the pituitary gland. IGF-I is the actual mediator of several effects attributed to GH, including increased skeletal muscle mass and bone growth (1) . In cultured neonatal ventricular myocytes, the addition of IGF-I induces DNA synthesis (2) (3) and the transcription of several genes associated with hypertrophy and hyperplasia, including myosin light chain-2, troponin and ␣-skeletal actin (4) . The addition of IGF-I to adult cultured cardiomyocytes induces only a hypertrophic response, characterized by increased myofibril production (5) .
In vivo, IGF-I and its receptor are up-regulated in experimentally infarcted ventricles, possibly followed by DNA replication and mitotic division of a portion of the remaining cardiomyocytes (6, 7) . IGF-I protects against apoptosis in cultured (8) and primary cardiomyocytes (9) and in a mouse model of ischemic injury (10) . A transgenic mouse with significantly increased IGF-I serum levels exhibits cardiomyocyte hyperplasia but no hypertrophy (11) . IGF-I and/or GH have been shown to improve cardiac performance in experimental (12, 13) and human patient cardiac failure (14, 15) . Consequently, IGF-I and GH are being seriously considered as potential therapeutic agents for situations in which hypertrophy and/or hyperplasia of cardiomyocytes would be desirable, such as postmyocardial infarction or hypocontracting cardiomyopathies (16, 17) .
In contrast to these beneficial effects, however, IGF-I has been implicated as a primary factor in the development of cardiac hypertrophy under conditions of pressure overload (18) . IGF-I stimulates collagen production in primary cultures of mechanically loaded cardiac fibroblasts (19) and in hypertensive humans (20) . Patients with hypersecretion of GH (acromegaly), and consequently IGF-I, often develop a cardiomyopathy characterized by interstitial fibrosis, mononuclear infiltration, and myocyte necrosis (16) . Systolic dysfunction is a common late-stage finding in these patients (21) . Administration of octreotide, which inhibits GH secretion, can partially relieve these effects (22) . Given these conflicting observations, we considered it imperative to determine whether the long-term effects of IGF-I on cardiac function were of a physiological or pathological nature. Here we report that persistent expression of IGF-I in a transgenic model initially induced an analog of physiologic hypertrophy, characterized by increased cardiac mass and improved systolic performance. However, later in life this hypertrophy progressed to a pathological condition characterized by decreased systolic performance and increased interstitial fibrosis.
MATERIALS AND METHODS

Mice
The construction of the SIS2 transgene has been described (23) as Sk 733 IGF-I 3ЈSk. SIS2 transgenics and control mice were of the inbred FVB background strain. Control animals were either littermates lacking the SIS2 transgene or FVB controls purchased from Charles River Laboratories (Wilmington, Mass.). All animals were housed at Baylor College of Medicine in accordance with National Institutes of Health guidelines. Animals were kept on a 10 h light/14 h darkness schedule and were fed autoclaved chow ad libitum.
IGF-I radioimmunoassay
Rodent and human total IGF-I concentrations in serum and heart homogenates were determined by species-specific radioimmunoassay (Diagnostic Systems Labs, Webster, Tex.) (rodent) or IRMA (human). Serum samples were assayed per manufacturer's instructions. Heart homogenates were prepared by powdering whole mouse hearts under liquid N 2 suspension in 4°C RIPA buffer [phosphate-buffered saline (PBS), 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate] plus protease inhibitors [1 mg/ml Pefabloc (Boehringer Mannheim, Indianapolis, Ind.), 0.5 mg/ml EDTA, 10 g/ml pepstatin, 1 g/ml aprotinin)] and homogenized. Serum and heart homogenates' human and rodent IGF-I levels were then assayed per manufacturer's instructions, except that homogenates were subjected to a single freeze/thaw cycle prior to assay to increase recovery of the hormone.
Pulsed Doppler measurements of systolic performance
Our method for pulsed Doppler measurements has been described (24) .
Immunohistochemistry
Hearts from control and SIS2 mice were excised, blotted dry, and flash frozen in 2-methyl-butane chilled with liquid N 2 . Tissue sections (6 M) were produced and mounted on polylysine-coated slides. Slides were fixed at Ϫ20°C for 20 min in 50 mM glycine in 70% ethanol adjusted to pH 2.0. A 1:20 dilution of conditioned media from a hybridoma expressing anti-rat sarcomeric myosin IgG (hybridoma MF20, University of Iowa Developmental Studies Hybridoma Bank, Iowa City) was applied to the slides for 30 min. Slides were rinsed three times for 5 min with PBS. An FITC-conjugated sheep antimouse IgG secondary antibody (Boehringer Mannheim) was applied to slides for 30 min. Slides were rinsed three times for 5 min with PBS. A 200 ng/ml Hoechst 33258 solution was applied to slides for 5 min to stain nuclei.
Fibrosis quantitation
After paraffin embedding, 4 M sections were produced and mounted on polylysine-coated slides. Slides were stained with Sirius red/picric acid. Overlapping partial images of heart cross sections were captured at 40ϫ with a microscopemounted digital camera. Composite images of complete heart cross sections were assembled and quantitation of collagen and noncollagen material was performed.
Statistical analysis
Data sets were compared using Student's t test, the nonparametric sign test, or analysis of variance, as appropriate. P Ͻ 0.05 was considered significant. Results are reported as mean Ϯ standard error.
RESULTS
Expression of the SIS2 transgene
Expression of the SIS2 (␣-skeletal actin promoter, human IGF-I cDNA, ␣-skeletal actin 3ЈUTR) transgene had been partially characterized in a previous study (23) , which showed transgenic mRNA only in skeletal and cardiac muscle, with skeletal expression being greater than that of cardiac. In the current study, changes in transgene expression with age were examined. Transgenic (i.e., human) and endogenous IGF-I levels in serum and heart homogenates were measured by IRMA or radioimmunoassay at 10, 20, and 32 wk of age (Fig. 1A, B) . Human IGF-I (hIGF-I) was detected in transgenic serum at every time point; serum from control mice contained no detectable hIGF-I. The serum level of endogenous IGF-I declined with age in both control and transgenic mice. There was no statistically significant difference in endogenous IGF-I levels between transgenic and control serum samples at any age, implying that the SIS2 transgene was not repressing ex-pression of the endogenous IGF-I gene. Total (humanϩmouse) serum IGF-I was not significantly different between transgenics and controls at any time point.
As with serum, hIGF-I was detected in SIS2 hearts at each time point, but not in control hearts. The level of endogenous IGF-I declined with age in both control and transgenic hearts. There was no statistically significant difference in the endogenous IGF-I level between control and transgenic heart homogenates at any age, suggesting that the transgene's expression was not repressing that of the endogenous IGF-I gene. However, total heart IGF-I was significantly increased ϳthreefold by 10 wk of age in transgenic mice compared to controls (29.9Ϯ4.4 vs. 11.8Ϯ3.2 ng/mg, PϽ0.003). This difference increased to fivefold by 20 wk of age (42.7Ϯ5.5 vs. 8.3Ϯ2.3 ng/mg, PϽ0.0001). Overall, these data indicate that the SIS2 transgene induces its phenotype primarily through enhanced local, cardiac IGF-I expression.
The SIS2 mouse develops cardiac hypertrophy
To determine the extent to which the SIS2 transgene is able to induce cardiac hypertrophy, cardiac mass and tibial length were measured in control and SIS2 mice at 10, 20, and 32 wk of age. Cardiac mass (Fig.  1C) 
IGF-I is initially beneficial, but ultimately detrimental to systolic function
Having established that the SIS2 transgene can induce cardiac hypertrophy, we then examined the long-term effect of IGF-I on systolic function ( Fig. 2A) . Eight SIS2 mice and eight control littermates were subjected to aortic-pulsed Doppler measurements in a longitudinal study. Data were collected at 10, 20, 32, and 52 wk of age. Peak aortic outflow velocity, a measure of systolic performance, was significantly greater (111.9Ϯ6.2 vs. 87.6Ϯ3.8 cm/s; PϽ0.02) in the transgenics at 10 wk compared to controls. This benefit, however, was not maintained; transgenic peak aortic outflow velocity was not significantly different from controls at 20 or 32 wk and was significantly reduced (95.3Ϯ4.0 vs. 112.1Ϯ4.9 cm/s; PϽ0.05) by 52 wk compared to controls. Heart rates were not significantly different between control and transgenic animals at any time point (Table 1) . Thus, IGF-I expression provided a temporary systolic performance benefit early in life, but continued expression led to compromised performance.
SIS2 mice exhibit reduced left ventricular early/ atrial peak filling velocity ratios
The accretive gain in cardiac mass and transient increase in peak aortic outflow velocity observed in SIS2 mice compared to controls might be explained by a steady degradation of left ventricular diastolic function. To test this hypothesis, early/atrial peak filling velocity ratios measured by transmitral pulsed Doppler were examined (Fig. 2B ). E/A peak velocity ratios were consistently lower in SIS2 mice than in controls. When all time points were considered simultaneously, SIS2 mice demonstrated a significant reduction in early/atrial peak filling velocities (PϽ0.03). Heart rates were not different between groups at any time point. Thus, it is likely that the long-term effect of a loss of left ventricular compliance or impairment of relaxation is at least partially responsible for the systolic performance changes present in the SIS2 mouse.
Histological findings in SIS2 mice
Having observed that the SIS2 transgene provides a short-term systolic performance benefit but a longterm detriment, we searched for structural differences between transgenic and control mice that could provide a rationale for the functional effect. Hearts from 52-wk-old transgenic and littermate control mice were sectioned and immunostained for sarcomeric myosin (Fig. 3) . Control heart sections displayed uniform myosin expression. A few punctate regions lacking myosin expression were determined to be nuclei on counterstaining with Hoechst 33258. These findings contrasted sharply with those of the transgenic heart sections. In these, myosin expression was intermittent; large areas were devoid of myosin protein. Most of these nonmyosin regions were not nuclei, as they failed to stain with Hoechst 33258. Sections from transgenic hearts also revealed dramatic myofiber hypertrophy; myofiber disorganization was evident in some transgenic sections. Myofiber hypertrophy and disorganization are common elements of pathological cardiac hypertrophy. Regions of the transgenic sections that failed to stain with sarcomeric myosin antibody or Hoechsht 33258 might be explained by yet another feature of pathological hypertrophy, interstitial fibrosis.
To test the hypothesis that these regions contained collagen, all mice from the longitudinal study were killed at 72 wk of age and their hearts were fixed for histological examination. Upon dissection, transgenics displayed wide variability in cardiac mass compared to controls (188.4Ϯ22.0 mg vs. 151.7Ϯ14.4 mg, PϽ0.05). Some 72 wk transgenic mouse hearts exhibited overt organ pathology (Fig. 4A) . Individual myofibers from some transgenic heart sections were hypertrophied severalfold compared to controls (Fig. 4B ), but this varied with the degree of cardiac hypertrophy in each mouse. To determine the extent of interstitial fibrosis, sections from each longitudinal study heart were stained with Sirius red, which binds collagen quantitatively. Transgenic hearts (72-wk-old) demonstrated a significantly greater percentage of fibrosis per complete cross section (12.0Ϯ2.0 vs. 3.3Ϯ0.5%, PϽ0.01) compared to controls (Fig. 4C) . Thus, it is likely that the nonmyosin, nonnuclear regions in sections from 52-wk-old transgenic also contained collagen. The significantly decreased systolic performance seen in aged SIS2 mice corresponded with their increased cardiac interstitial fibrosis.
We also examined young SIS2 mice to determine whether the converse held true. Sirius red-stained heart sections from 15-wk-old transgenic mice trended toward increased fibrosis compared to controls, but did not achieve statistical significance (7.8Ϯ1.2 vs. 4.4Ϯ0.5%, PϽ0.08). Myofiber disorganization was not evident and myofiber hypertrophy was marginal in 15-wk-old transgenic mice. Although a cause-and-effect relationship cannot be proved, erosion of the temporary benefit in systolic performance conferred by the SIS2 transgene closely paralleled the development of interstitial fibrosis.
DISCUSSION
The development of pressure overload-induced cardiac hypertrophy has been shown to be concomitant with increased IGF-I expression by the heart (18). We present evidence that cardiac expression of IGF-I in the absence of significantly increased serum IGF-I is sufficient to initiate and promote an analog of physiologic cardiac hypertrophy, which eventually progresses to a pathological state. The phenotypic progression of the SIS2 mouse closely parallels that of the mammalian heart in hypertension. In the early stages of mammalian hypertension, individual myocytes increase the number of myofibers they contain in an attempt to normalize the increased systolic pressure applied to them. Grossly, the heart begins to develop a concentric hypertrophy of the left ventricle. A microscopic examination of the heart at this stage reveals hypertrophy of well-organized myocytes, but fibrosis and myofiber disorganization are not yet evident. From a functional standpoint, the heart effectively compensates for its high-pressure operating environment, as there is no loss in cardiac output. In the present study, the SIS2 mouse developed statistically significant increases in cardiac mass and cardiac mass/tibial length by 10 wk of age, but neither myofiber disorganization nor statistically significant fibrosis had developed by 15 wk. The hypertrophy in 10 wk SIS2 mice actually provided an increase in systolic performance when compared to controls. Thus, young SIS2 mice present an analog of physiologic cardiac hypertrophy. Were pressure overload actually present, these findings might well be classified as compensated pathologic hypertrophy, and it is this early phenotypic stage of hypertensive heart disease for which the young SIS2 mouse may be an effective model.
With severe or even mild but persistent hypertension, the mammalian heart will undergo further hypertrophy until the phenotype progresses to a more pathological state. Grossly, this is characterized by pronounced concentric hypertrophy of the left ventricle. Other chambers may reveal pathological anatomic changes as well. Microscopically, the pathologically hypertrophied heart reveals prominent hypertrophy of individual myocytes, disorganization of myofibers, and increased interstitial fibrosis. Despite the increased heart mass and consequent increase in oxygen and metabolite consumption, cardiac output actually declines. Often this is due to a loss of ventricular compliance. In effect, the thicker ventricular wall and its increased collagen content lead to less efficient diastolic filling. In a similar fashion, the SIS2 mouse exhibits a progressive development of pathological features as the animal matures. The statistically significant increases in cardiac mass and cardiac mass/tibial length that SIS2 mice exhibit by 10 wk of age become more pronounced with age. Histological examination of 72-wk-old SIS2 mice revealed hypertrophy of individual myocytes and significantly increased interstitial fibrosis when compared to controls. Despite the increased cardiac hypertrophy, the SIS2 transgenic mouse's systolic function steadily deteriorates from 10 wk of age (if not earlier) until it is significantly worse than that of control mice (at 52 wk). Although no relative decrease over time was evident, early/atrial peak filling velocity ratios were also significantly reduced in SIS2 transgenic mice compared to controls, indicating that diastolic function may also be compromised in this animal model. The IGF-I expression pattern and the phenotype progression observed in the SIS2 mouse may make this animal an informative model for pressure overload-induced cardiac hypertrophy.
No model is perfect, but we believe the limitations inherent in the SIS2 mouse model are outweighed by its potential utility. Given the increase in skeletal muscle mass seen in the SIS2 mouse (23) , it could be argued that increased metabolic demand by peripheral tissues is the primary factor driving the development of cardiac hypertrophy. However, the presence or absence of the SIS2 transgene was the only statistically significant factor in determining cardiac mass after normalizing cardiac mass to lean body mass, a metric dominated by skeletal muscle mass (data not shown). Combined with the statistically significant increase in hIGF-I detected in the SIS2 mouse heart, these data suggest that the transgene exerts a direct hypertrophic effect on cardiac tissue. If present, changes in afterload resistance might account for the majority of this study's reported differences in systolic performance between SIS2 and control mice. We did not measure systemic aortic blood pressure on a longitudinal basis in this study, as this would have required repeated catheterization. The possible presence of vascular hypertrophy was examined as part of the original characterization of the SIS2 mouse, but no evidence of this phenomenon was found. This information is corroborated by the lack of transgene mRNA expression in smooth muscle tissue (23) and by the lack of significant circulating hIGF-I in the current study.
Peak aortic outflow velocity is also sensitive to changes in preload and heart rate. Heart rate was not significantly different among transgenic and control animals at any time point in this study (Table 1) . This study does present evidence of decreased early/ atrial peak filling velocity ratios in SIS2 mice compared to controls, suggesting that diastolic function is compromised in the transgenic animals. However, it is important to note that the greatest deficit in transgenic E/A peak velocity ratios compared to control values occurs at 10 wk of age, when the transgenic animals' peak aortic outflow velocity is 128% of the control value. At 52 wk of age, peak aortic outflow velocity of SIS2 mice is only 85% of that of control mice, but the relative difference between transgenic and control E/A peak velocity ratios is essentially unchanged from the 10 wk time point. This lack of correlation between the relative decline in peak aortic outflow velocity and the relative E/A peak velocity ratio strongly suggests that preload changes alone are unlikely to account for the erosion of systolic performance in the SIS2 transgenic mouse.
The well-documented ability of IGF-I to improve cardiac performance, at least temporarily, in clinical (15) and experimental (12, 25) cardiac pathologies has sparked much interest in the use of this hormone as a novel therapy in the failing heart. Here we examined the cardiac effect of local IGF-I expression throughout the majority of an animal model's life span. This long-term perspective has proved to be of critical importance. We confirmed the short-term benefit in systolic performance After IGF-I administration reported in other studies. However, we have determined that this benefit is transient, and that with continued exposure to IGF-I, the heart develops pathological features including reduced systolic performance and marked interstitial fibrosis. Our demonstration that IGF-I ultimately compromises cardiac function and induces undesirable cellular changes in the heart may limit the therapeutic potential of chronic IGF-I administration. Consequently, the potential cardiovascular benefits of IGF-I must be carefully balanced against the potential dangers inherent in stimulation by this growth factor. Considering our findings, limiting temporal exposure to IGF-I seems the most efficacious means of delivering the potential benefits of IGF-I while avoiding its deleterious side effects.
